About Melanoma-associated antigen 10
Melanoma-associated antigen 10 (MAGEA10) is a protein
from Homo sapiens identified by UniProt accession
P43363, 369 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Melanoma-associated antigen 10 |
|---|
| UniProt accession | P43363 |
|---|
| Gene | MAGEA10 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 369 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (42)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.20
- osteoarthritis · score 0.09
- neoplasm · score 0.05
- pancreatic adenocarcinoma · score 0.04
- breast carcinoma · score 0.04
- melanoma · score 0.03
- non-small cell lung carcinoma · score 0.02
- hepatocellular carcinoma · score 0.02
- cancer · score 0.02
- breast ductal carcinoma in situ · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P43363-F1 | alphafold | PREDICTED | 72.75 | — |
Amino-acid sequence (369 residues)
MPRAPKRQRC MPEEDLQSQS ETQGLEGAQA PLAVEEDASS STSTSSSFPS SFPSSSSSSS SSCYPLIPST PEEVSADDET PNPPQSAQIA CSSPSVVASL PLDQSDEGSS SQKEESPSTL QVLPDSESLP RSEIDEKVTD LVQFLLFKYQ MKEPITKAEI LESVIRNYED HFPLLFSEAS ECMLLVFGID VKEVDPTGHS FVLVTSLGLT YDGMLSDVQS MPKTGILILI LSIVFIEGYC TPEEVIWEAL NMMGLYDGME HLIYGEPRKL LTQDWVQENY LEYRQVPGSD PARYEFLWGP RAHAEIRKMS LLKFLAKVNG SDPRSFPLWY EEALKDEEER AQDRIATTDD TTAMASASSS ATGSFSYPE
Explore Melanoma-associated antigen 10 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets